中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
10期
555-559
,共5页
庞春光%孙保存%赵秀兰%刘志勇%古强%董学易%马跃美%孙丹
龐春光%孫保存%趙秀蘭%劉誌勇%古彊%董學易%馬躍美%孫丹
방춘광%손보존%조수란%류지용%고강%동학역%마약미%손단
大肠癌%血管生成拟态%αvβ3 integrin%表达%临床预后
大腸癌%血管生成擬態%αvβ3 integrin%錶達%臨床預後
대장암%혈관생성의태%αvβ3 integrin%표체%림상예후
colorectal cancer%vasculogenic mimicry%αvβ3 integrin%molecular mechanism%clinical prognosis
目的:探讨大肠癌中是否存在血管生成拟态(VM),阐述VM存在的临床意义;分析VM与αvβ3 integrin表达的关系;研究大肠癌中αvβ3 integrin表达的临床意义及其与FAK、MMP-2、VEGF表达的相关性.方法:对227例大肠癌组织切片进行CD31免疫组织化学和PAS染色及αvβ3 integrin、FAK、VEGF、MMP-2免疫组织化学染色.结果:VM在大肠癌中阳性率为18.06%(41/227),αvβ3 integrin在大肠癌中阳性率为56.83%(129/227);VM阳性组、αvβ3 integrin阳性组生存时间均较阴性组短,差异均有统计学意义(P<0.05);VM阳性组的αvβ3 integrin阳性率较阴性组高,差异有统计学意义(P<0.05);αvβ3 integrin与FAK、VEGF、MMP-2表达呈正相关.结论:大肠癌中VM的存在、αvβ3 integrin的表达与肿瘤的不良预后有关;αvβ3 integrin可能通过与FAK、VEGF、MMP-2的相互作用,参与了大肠癌VM的形成.
目的:探討大腸癌中是否存在血管生成擬態(VM),闡述VM存在的臨床意義;分析VM與αvβ3 integrin錶達的關繫;研究大腸癌中αvβ3 integrin錶達的臨床意義及其與FAK、MMP-2、VEGF錶達的相關性.方法:對227例大腸癌組織切片進行CD31免疫組織化學和PAS染色及αvβ3 integrin、FAK、VEGF、MMP-2免疫組織化學染色.結果:VM在大腸癌中暘性率為18.06%(41/227),αvβ3 integrin在大腸癌中暘性率為56.83%(129/227);VM暘性組、αvβ3 integrin暘性組生存時間均較陰性組短,差異均有統計學意義(P<0.05);VM暘性組的αvβ3 integrin暘性率較陰性組高,差異有統計學意義(P<0.05);αvβ3 integrin與FAK、VEGF、MMP-2錶達呈正相關.結論:大腸癌中VM的存在、αvβ3 integrin的錶達與腫瘤的不良預後有關;αvβ3 integrin可能通過與FAK、VEGF、MMP-2的相互作用,參與瞭大腸癌VM的形成.
목적:탐토대장암중시부존재혈관생성의태(VM),천술VM존재적림상의의;분석VM여αvβ3 integrin표체적관계;연구대장암중αvβ3 integrin표체적림상의의급기여FAK、MMP-2、VEGF표체적상관성.방법:대227례대장암조직절편진행CD31면역조직화학화PAS염색급αvβ3 integrin、FAK、VEGF、MMP-2면역조직화학염색.결과:VM재대장암중양성솔위18.06%(41/227),αvβ3 integrin재대장암중양성솔위56.83%(129/227);VM양성조、αvβ3 integrin양성조생존시간균교음성조단,차이균유통계학의의(P<0.05);VM양성조적αvβ3 integrin양성솔교음성조고,차이유통계학의의(P<0.05);αvβ3 integrin여FAK、VEGF、MMP-2표체정정상관.결론:대장암중VM적존재、αvβ3 integrin적표체여종류적불량예후유관;αvβ3 integrin가능통과여FAK、VEGF、MMP-2적상호작용,삼여료대장암VM적형성.
This work aimed to investigate the expression and clinical significance of vasculogenic mimicry (VM), to analyze the relationship between VM andαvβ3 integrin expressions, and to study the clinical significance ofαvβ3 integrin expression and its correlation with the Focal Adhesion Kinase (FAK), Vascular Endothelial Growth Factor (VEGF), and Matrix Metalloproteinase 2 (MMP-2) expression. Methods:VM expression was observed by CD31 immunohistochemical and PAS staining. Expression ofαvβ3 integrin, FAK, VEGF, and MMP-2 was observed by immunohistochemical staining. Results:Results showed that VM andαvβ3 integ-rin had positive rates of 18.06%(41/227) and 56.83%(129/227), respectively. Patients with VM expression had a shorter survival time than those without VM expression (P<0.05).αvβ3 integrin-positive patients had a shorter survival time thanαvβ3 integrin-negative pa-tients (P<0.05). Patients with VM expression showed a higher positive rate of αvβ3 integrin than those without VM expression (P<0.05), andαvβ3 integrin had a positive correlation with FAK, MMP-2, and VEGF expression. Conclusion:The incidence of VM andαvβ3 integrin expressions in human colorectal cancer cases indicates a poor prognosis.αvβ3 integrin possibly participates in the formation of VM through interactions with FAK, VEGF, and MMP-2.